Open Access

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin

  • Melina Herrera1,
  • Sabrina Di Gregorio2,
  • Silvina Fernandez2,
  • Graciela Posse1,
  • Marta Mollerach2 and
  • José Di Conza1, 2, 3Email author
Annals of Clinical Microbiology and Antimicrobials201615:15

https://doi.org/10.1186/s12941-016-0131-7

Received: 22 October 2015

Accepted: 29 February 2016

Published: 8 March 2016

Abstract

Background

Tigecycline (TIG) is an antibiotic belonging to the glycylcyclines class and appears to be a good choice to fight infections caused by Staphylococcus aureus. To date, TIG exhibits good activity against this microorganism. The aim of this work was to obtain in vitro mutants of S. aureus resistant to TIG and evaluate possible changes in their susceptibility patterns to other antibiotics.

Results

Two mutants of S. aureus resistant to TIG (MIC = 16 µg/mL) were selected in vitro from clinical isolates of methicillin-resistant S. aureus. In both mutants, corresponding to different lineage (ST5 and ST239), an increase of efflux activity against TIG was detected. One mutant also showed a reduced susceptibility to vancomycin, corresponding to the VISA phenotype (MIC = 4 µg/mL), with a loss of functionality of the agr locus. The emergence of the VISA phenotype was accompanied by an increase in oxacillin and cefoxitin MICs.

Conclusions

This study demonstrates that, under selective pressure, the increase of efflux activity in S. aureus is one of the mechanisms that may be involved in the emergence of tigecycline resistance. The emergence of this phenotype may eventually be associated to changes in susceptibility to other antibiotics such oxacillin and vancomycin.

Keywords

MRSA Tigecycline resistant Efflux activity VISA

Findings

Staphylococcus aureus is one of the major pathogens causing serious infections both within the hospital setting and in the community. This pathogen is characterized by rapid acquisition of resistance to antibiotics introduced into clinical practice. Thus, methicillin-resistant S. aureus (MRSA) emerged first in the hospital setting and then spread to the community (CA-MRSA) [1]. In the late 1990s, MRSA strains emerged with reduced susceptibility to vancomycin, VISA (vancomycin-intermediate S. aureus) [2] and VRSA (vancomycin-resistant S. aureus) [3]. Tigecycline (TIG) is an antibiotic belonging to the glycylcyclines class and representing a treatment option for infections caused by S. aureus [4]. Surveillance studies of S. aureus have exhibited good activity of this antibiotic, with 99.9 % of isolates found to be susceptible [5]. A high susceptibility rate was also reported in Latin America from 2004 to 2010 [6] and in several countries around the world [7, 8]. The aim of this work was to select and characterize in vitro tigecycline-resistant mutants from MRSA clinical isolates.

Two unrelated MRSA clinical isolates (2028p and 94159p) were studied. They were genotyped by spa typing [9], and the multilocus sequence type (MLST) was determined using the S. aureus MLST database (http://www.mlst.net).

Oxacillin resistance was confirmed by PCR amplification of an internal fragment of the mecA gene. S. aureus strains ATCC 29213 and ATCC 43300 were used as negative and positive controls, respectively.

The SCCmec type was determined by characterization of the ccr complex (cassette chromosome recombinase) and the mec complex, using a simplified version of the previously described scheme [10]. The agr type was characterized by multiplex PCR [11], and analysis of agr functionality was performed by determining δ-hemolysin production according to Traber et al. [12]. Briefly, it was conducted by cross-streaking test strains perpendicularly to S. aureus RN4220, which only produces β-hemolysin on a sheep blood agar plate. δ-hemolysin acts synergistically in the lysis of sheep red blood cells and generates a zone of enhanced hemolysis at the intersection of RN4220 and test strain streaks.

In vitro mutant selection was performed by serial passage in Mueller–Hinton broth (Britania, Argentina) with increasing concentrations of TIG (Pfizer, USA), starting from a sub-inhibitory concentration corresponding to ¼ minimum inhibitory concentration (MIC) to MIC values, using an inoculum of 5 × 105 CFU/mL. Colonies were selected after 15 passages [13]. The MIC of TIG was determined by the epsilometric method, considering the FDA breakpoints. Mutant stability was evaluated by determining the TIG MIC after 10 consecutive passages in antibiotic-free Tryptic-Soy Agar (Britania, Argentina). The clonal relationship between the parental strains and the mutants was confirmed by pulsed-field gel electrophoresis (PFGE) using the SmaI endonuclease [14]. Susceptibility to other classes of antibiotics was tested by the agar dilution method following the Clinical and Laboratory Standards Institute recommendations (CLSI, 2013). The antibiotics tested were oxacillin (OXA), cefoxitin (FOX), trimethoprim-sulfamethoxazole (TMS), rifampicin (RIF) (Sigma-Aldrich, USA), gentamicin (GEN), ciprofloxacin (CIP), clindamycin (CLI) and vancomycin (VAN) (Fada Pharma, Argentina).

Finally, efflux activity was phenotypically evaluated as a potential mechanism of resistance to TIG by comparing the MICs of TIG and ethidium bromide (EB) in the presence and absence of reserpine (RS) (20 µg/mL). An EB MIC of ≥32 µg/mL, coupled with a reduction of at least 4 twofold dilutions (TFD) in the MICs of EB and TIG in the presence of RS, was considered to be indicative of an enhancement of efflux activity. This criterion combines the canons proposed by Patel et al. [15] (EB MIC ≥25 µg/mL) and DeMarco et al. [16] (MIC reduction of 4 TFD in the presence of RS).

The two TIG-resistant mutants were obtained from the two MRSA parental strains, 2028 and 94159p, and named 2028 and 94159m, respectively. The parental and mutant strains were isogenic (Fig. 1). Both mutants exhibited TIG MIC values, which were 128-fold higher than those against the parental strains. The MIC data and molecular characteristics of the strains are summarized in Table 1.
Fig. 1

SmaI-PFGE of the parental and mutant strains. Lane 1: parental strain 2028p, lane 2: mutant strain 2028 m, lane 3: parental strain 94159p, lane 4: mutant strain 94159 m

Table 1

Molecular and phenotypic characterization of two TIG-resistant mutants and MRSA parental strains

Strains

Molecular characterization

MIC (μg/mL)

δ-hemolysin

SCC mec

ST

spa type

agr

group

OXA

FOX

VAN

TMS

RIF

CIP

GEN

CLI

TIG

TIG + RS

EB

EB + RS

OXA + RS

FOX + RS

VAN + RES

2028p

III

239

t654

I

≥32

≥128

1

≥32/608

≥16

≥16

≥64

≥8

0125

0.064

16

2

ND

ND

ND

+

2028m

III

239

t654

I

≥32

≥128

1

≥32/608

≥16

≥16

≥64

≥8

16

0.25

64

2

ND

ND

ND

+

94159p

IV

5

t002

II

8

16

1

0.5/9.5

4

0.5

≥64

≤0.25

0125

0.064

16

1

16

16

1

+

94159m

IV

5

t002

II

32

64

4

0.5/9.5

4

0.5

≥64

≤0.25

16

1

128

8

32

64

4

p parental, m mutant, ST sequence type, OXA oxacillin, FOX cefoxitin, VAN vancomycin, TMS trimethoprim sulfamethoxazole, RIF rifampicin, GEN gentamicin, CLI clindamycin, TIG tigecycline, RS reserpine, EB ethidium bromide, ND not determined

Unlike the parental strains, both mutants showed a decrease of ≥4 TFD in EB and TIG MICs in the presence of RS (Table 1), which suggested that an increase in efflux pump activity could be involved in TIG resistance. It is well known that efflux pumps in S. aureus have the ability to expel more than a few antibiotics in addition to other compounds such as biocides and dyes [17]. The increase of efflux activity is one of the mechanisms involved in resistance of S. aureus to several antibiotics, due to which strains become refractory to treatments with those antibiotics [18].

To date, naturally occurring S. aureus isolates with reduced susceptibility to tigecycline (MICs of 1–2 µg/mL) have been isolated from clinical specimens [5, 6]. However, the high MIC values (16 µg/mL) of these in vitro selected mutants should be considered a potential risk in clinical settings. It is important to highlight that no significant fitness cost associated with the selection of these mutants was detected (data not shown).

In addition, TIG-resistant mutant 94159 m was also characterized by a changed susceptibility profile to OXA, FOX, and VAN. It is important to highlight that the VAN MIC value of this mutant is 4 µg/mL, thus corresponding to the VISA definition (Table 1).

An increase in the VAN MIC was previously associated with a reduction in the OXA MIC in both in vitro selected VRSA mutants and in vivo VISA isolates [19, 20]. By contrast, in this case the emergence of the VISA phenotype is accompanied by an increase in OXA and FOX MIC values in the 94159m strain.

The MIC values of OXA, FOX and VAN for 94159m remain unchanged in the presence of RS (Table 1) suggesting a different mechanism to that observed for TIG resistance.

Based on molecular typing, the 94159p strain was characterized as ST5, SCCmec IV, spa-type t002, indicating that it belonged to the main CA-MRSA clone that circulated in Argentina at the time when this strain was isolated [21, 22]. The increased ability to acquire new resistance determinants and the capacity of surviving in different environments have been associated with a great genomic plasticity of clonal complex 5 (CC5). The majority of heterogeneous VISA (hVISA), VISA and VRSA isolates belong to this lineage [23, 24]. Likewise, an emergence of CC5 hVISA isolates has recently been reported in Argentina [25]. Finally, a loss of δ-hemolysin expression in the VISA 94159m mutant was another characteristic observed in this work (Fig. 2). An association between reduced susceptibility to VAN and the loss of the agr function was described previously [26].
Fig. 2

δ-Hemolysin assays. The strain streaked vertically is β-hemolysin-producing RN4220. Strain N315 was used as a negative control. a A zone of enhanced hemolysis by strain 94159p is seen as an arrowhead (δ-hemolysin); the δ-hemolytic capacity has been lost by strain 94159 m. b Strains 2028p and 2028 m both produce β- and δ-hemolysins

Strain 2028p (ST239, SCCmec III, spa-type t654) was shown to belong to the Brazilian clone, a multi-resistant HA-MRSA clone that was prevalent in Argentina in 2005. Contrary to the behavior of 94159m, mutant 2028m did not show any modification in either the VAN MIC or in the agr functionality. In this work, the ability of S. aureus to develop resistance to TIG under selective pressure with this antibiotic was shown, and the increase of efflux activity is considered to be one of the possible resistance mechanisms involved. The selection of TIG mutants in two different lineages indicates that this event is not limited to a particular genetic background. Furthermore, the data show that, in a particular strain, the acquisition of this resistance may be associated with reduced susceptibilities to vancomycin and some other antibiotics such as oxacillin. The literature data suggest that the phenomenon of elevated vancomycin MICs, coupled with the loss of δ-hemolysin expression, appears to be common to different geographical regions [27]. Importantly, while the emergence of resistance to tigecycline and vancomycin can occur, the absence of high-level resistance to these antibiotics is noteworthy [5]. It is important to be aware of this potential risk and, wherever possible, emphasize the necessity to use appropriate and adequate drug dosing regimens to prevent it.

Availability of supporting data

The data set supporting the results of this article is included within the article.

Declarations

Authors’ contributions

JDC and MM proposed and designed the study and analyzed the generated data; MH, SDG, SF and GP carried out the experimental part of the manuscript, GP provided the clinical strains for the study; MH, SDG, JDC and MM helped to draft the manuscript and in critical revision. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by a grant from the Facultad de Ciencias de la Salud, Universidad Adventista del Plata. Libertador San Martín, Entre Ríos. JDC and MM are members of ‘‘Carrera del Investigador’’ of CONICET. SDG is a post-doctoral fellow of CONICET.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Facultad de Ciencias de la Salud, Universidad Adventista del Plata
(2)
Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
(3)
Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral

References

  1. Chambers HF, De Leo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629–41.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104:7–10.View ArticleGoogle Scholar
  3. Chang S, Sievert D, Hageman J, Boulton M, Tenover F, Downes F, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7.View ArticlePubMedGoogle Scholar
  4. Stein G, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75:331–6.View ArticlePubMedGoogle Scholar
  5. Hoban D, Reinert R, Bouchillon S, Dowzicky M. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004–2013. Ann Clin Microbiol Antimicrob. 2015;10:14–27.Google Scholar
  6. Garza-González E, Dowzicky M. Changes in Staphylococcus aureus susceptibility across Latin America between 2004–2010. Braz J Infect Dis. 2013;17:13–9.View ArticlePubMedGoogle Scholar
  7. Balode A, Punda-Polic V, Dowzicky M. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004–2010. Int J Antimicrob Agents. 2013;41:527–35.View ArticlePubMedGoogle Scholar
  8. Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from US medical centers since its approval for clinical use (2006–2012). Antimicrob Agents Chemother. 2014;58:2274–80.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Hallin M, Deplano A, Denis O, De Mendonça R, De Ryck R, Struelens MJ. Validation of pulsed-field gel electrophoresis and spa typing for long-term, nationwide epidemiological surveillance studies of Staphylococcus aureus infections. J Clin Microbiol. 2007;45:127–33.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother. 2007;51:264–74.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Gilot P, Lina G, Cochard T, Poutrel B. Analysis of the genetic variability of genes encoding the RNA III-activating components agr and TRAP in a Population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol. 2002;40:4060–7.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, et al. agr function in clinical Staphylococcus aureus isolates. Microbiology. 2008;154:2265–74.View ArticlePubMedGoogle Scholar
  13. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother. 2005;49:1865–71.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Chung M, de Lencastre H, Matthews P, Tomasz A, Adamsson M, Aires de Sousa M, et al. Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains. Microb Drug Resist. 2000;6:189–98.View ArticlePubMedGoogle Scholar
  15. Patel D, Kosmidis C, Seo SM, Kaatz G. Ethidium bromide MIC screening for enhanced efflux pump gene expression or efflux activity en Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5070–3.View ArticlePubMedPubMed CentralGoogle Scholar
  16. DeMarco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza TA, Kaatz GW. Efflux-related resistance to norfloxacin, dyes and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3235–9.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Huet A, Raygada J, Mendiratta K, Seo S, Kaatz G. Multidrug efflux pumps overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes. Microbiology. 2008;154:3144–53.View ArticlePubMedGoogle Scholar
  18. Santos Costa S, Viveiros M, Amaral L, Couto I. Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J. 2013;7:59–71.View ArticleGoogle Scholar
  19. Naimi TS, Anderson D, O’Boyle C, Boxrud DJ, Johnson SK, Tenover FC, et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003;36:1609–12.View ArticlePubMedGoogle Scholar
  20. Siradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin- resistant S. aureus under the impact of antibiotics administered for a chemotherapy. J Clin Microbiol. 2003;41:1687–93.View ArticleGoogle Scholar
  21. Sola C, Cortes P, Saka HA, Vindel A, Bocco JL. Evolution and molecular characterization of methicillin-resistant Staphylococcus aureus epidemic and sporadic clones in Cordoba. Argentina. J Clinical Microbiol. 2006;44:192–200.View ArticleGoogle Scholar
  22. Gardella N, von Specht M, Curiolo A, Rosato A, Gutkind G, Mollerach M. Community-associated methicillin-resistant Staphylococcus aureus, eastern Argentina. Diagn Microbiol Infect Dis. 2008;62:343–7.View ArticlePubMedGoogle Scholar
  23. Howe RA, Monk A, Wotton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis. 2004;10:855–7.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kos VN, Desjardins CA, Griggs A, Cerqueira G, Van Tonder A, Holden MT, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with methicillin-resistant S. aureus hospital-acquired infection in the United States. M Bio. 2012; doi: https://doi.org/10.1128/mBio.00112-12.
  25. Di Gregorio S, Perazzi B, Ordoñez AM, De Gregorio S, Foccoli M, Lasala MB, et al. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist. 2015;21:25–34.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis. 2003;187:929–38.View ArticlePubMedGoogle Scholar
  27. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002;46:1492–502.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Herrera et al. 2016

Advertisement